Product Description
A human monoclonal antibody directed against the inhibitory immune checkpoint receptor immunoglobulin-like transcript 4 (ILT4; leukocyte immunoglobulin-like receptor subfamily B member 2; LILRB2; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Upon administration, anti-ILT4 monoclonal antibody MK-4830 targets and binds to ILT4. This prevents the binding of ILT4 ligands to their receptor and prevents ILT4-mediated signaling. This abrogates the immunosuppressive activities of ILT4 in the tumor microenvironment (TME), activates the expression of pro-inflammatory cytokines, including GM-CSF and tumor necrosis factor alpha (TNFalpha), and enhances a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response. ILT4, plays a key role in tumor immune evasion. ILT4, a transmembrane protein and inhibitory member of the immunoglobulin-like transcript (ILT) family of proteins, is expressed primarily by myeloid cells, including monocytes, macrophages, dendritic cells (DCs) and granulocytes, and certain tumor cells. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ilt4-monoclonal-antibody-mk-4830)
Mechanisms of Action: ILT4 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Chile, China, France, Greece, Israel, Italy, Japan, Korea, Poland, Singapore, South Africa, South Korea, Spain, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Ovarian Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-4830-001 | P1 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-09-28 |
|
| Genomic and immune markers of response in ILT4- and pembrolizumab-treated ovarian cancer | P2 |
Active, not recruiting |
Ovarian Cancer |
2024-08-21 |
|
| MK-4830-002 | P2 |
Completed |
Ovarian Cancer |
2023-12-20 |
|
| jRCT2031210025 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2022-08-04 |